TARA ARGUELLES: Open Payments
NPI 1285282319 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$722 in 30 payments from 14 companies in 2025. Trend: 2023 $2,167 · 2024 $2,052 · 2025 $722
Food & beverage: $642Education: $80
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 6 | $125 |
| Eisai Inc. | 4 | $95 |
| Merck Sharp & Dohme LLC | 3 | $81 |
| SEAGEN INC. | 1 | $80 |
| ABBVIE INC. | 4 | $78 |
| Genmab U.S., Inc. | 2 | $67 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Novartis Pharmaceuticals Corporation | 2 | $34 |
| Genentech USA, Inc. | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
Products named: JEMPERLI, Lenvima, Tivdak, KEYTRUDA, EPKINLY, KISQALI, LYNPARZA, Venclexta.
Industry payments across AZ — which companies pay providers there.
